Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-hOC-E1
- Development stage
- Preclinical
- Lead developer
- China Medical University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Ad-hOC-E1 is an oncolytic adenovirus engineered for the treatment of advanced renal cell carcinoma (RCC). Its replication is transcriptionally regulated by the human osteocalcin (hOC) promoter, which is transcriptionally silent in most tissues but highly inducible by Vitamin D3. This design allows for a 'pharmaceutically-controlled' replication strategy. In preclinical studies, the virus is loaded into human bone marrow-derived mesenchymal stem cells (hMSCs), which act as carriers that home to tumor sites in response to PDGF-AA chemoattraction. Upon reaching the tumor, administration of Vitamin D3 induces the hOC promoter to drive the expression of the viral E1 gene, triggering viral replication and the subsequent lysis of RCC cells. This approach aims to improve the safety and efficacy of systemic oncolytic virotherapy by restricting viral activity to the tumor microenvironment and utilizing cell-based delivery to bypass immune clearance.
- Other names
- human osteocalcin promoter-directed Ad-hOC-E1 oncolytic adenovirus
02
Targets
CXADR (Coxsackievirus and adenovirus receptor)αVβ3 (Integrin αVβ3)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Ad-hOC-E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-hOC-E1.